| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000020704 |
| Receipt No. | R000022691 |
| Official scientific title of the study | Clinical trial of vitamin B12 treatment for impaired awareness of hypoglycemia accompanied with autonomic dysfunction in type 1 diabetes. |
| Date of disclosure of the study information | 2016/01/22 |
| Last modified on | 2018/01/22 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Clinical trial of vitamin B12 treatment for impaired awareness of hypoglycemia accompanied with autonomic dysfunction in type 1 diabetes. | |
| Title of the study (Brief title) | Clinical trial of vitamin B12 treatment for impaired awareness of hypoglycemia accompanied with autonomic dysfunction in type 1 diabetes. | |
| Region |
|
|
| Condition | |||
| Condition | type 1 diabetes | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To assess the efficacy of vitamin B12 treatment in type 1 diabetic patient with impaired awareness of hypoglycemia accompanied with autonomic dysfunction. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Symptoms of hypoglycemia in an insulin tolerance test(Day 21~28)). |
| Key secondary outcomes | Autonomic function(coefficient of variation of R-R interval, Schellong test)
Epinephrine, norepinephrine, dopamine, cortisol, ACTH, growth hormone, glucagon |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Vitamin B12 intramuscularly injection 1mg three times a week for 3 weeks | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Type 1 diabetes(Eligible participants had a known history of type 1 diabetes for at least 6 months, and had been treated for at least 6 months with a basal-bolus insulin regimen)
2)Treatment with multiple insulin injection 3)Hypoglycemia unawareness 4)Autonomic dysfunction |
|||
| Key exclusion criteria | 1)Patients younger than 19 years old.
2)Severe liver dysfunction 3)Severe renal failure 4)Pregnant 5)Judged as ineligible by clinical investigators |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Akihisa Imagawa |
| Organization | Graduate School of Medicine, Osaka University |
| Division name | Department of Metabolic Medicine |
| Address | 2-2-B5,Yamadaoka, Suita city, Osaka |
| TEL | 06-6879-5111 |
| aimagawa@endmet.med.osaka-u.ac.jp | |
| Public contact | |
| Name of contact person | Shingo Fujita |
| Organization | Graduate School of Medicine, Osaka University |
| Division name | Department of Metabolic Medicine |
| Address | 2-2-B5,Yamadaoka, Suita city, Osaka |
| TEL | 06-6879-5111 |
| Homepage URL | |
| lutefs222@endmet.med.osaka-u.ac.jp | |
| Sponsor | |
| Institute | Department of Metabolic Medicine, Graduate School of Medicine, Osaka University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Metabolic Medicine, Graduate School of Medicine, Osaka University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022691 |